--- title: "Eisai (TSE:4523) Posts First Quarter Growth, Is The Stock Fully Priced?" type: "News" locale: "en" url: "https://longbridge.com/en/news/295500208.md" description: "Eisai reported Q1 sales of ¥234.3 billion and net income of ¥18.2 billion, coinciding with a 15.2% share price rise over 30 days. Valuation views are mixed: one narrative suggests the stock is 10.4% overvalued at ¥4,949 against a fair value of ¥4,482, citing premium pricing power for LEQEMBI. Conversely, a DCF model indicates a 31.8% discount to an intrinsic value of ¥7,261. While structural reforms support profitability, risks include drug pricing scrutiny and reliance on key therapies." datetime: "2026-08-11T07:39:01.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295500208.md) - [en](https://longbridge.com/en/news/295500208.md) - [zh-HK](https://longbridge.com/zh-HK/news/295500208.md) generator: "portal-rs" --- # Eisai (TSE:4523) Posts First Quarter Growth, Is The Stock Fully Priced? Eisai (TSE:4523) recently reported first quarter earnings, with sales of ¥234,330 million, net income of ¥18,242 million, and basic earnings per share of ¥64.71 from continuing operations, drawing fresh attention to the stock. See our latest analysis for Eisai. Eisai's recent first quarter update has coincided with a strong 30-day share price return of 15.20% and a 1-year total shareholder return of 16.14%. However, total shareholder returns over three and five years are still lower, which suggests improving momentum after a weaker longer term run. If Eisai's recent move has you thinking more broadly about healthcare, this could be a good moment to look at other opportunities in the sector using our healthcare AI stock screener, starting with 7 healthcare AI stocks. Eisai now trades above the average analyst price target, yet the intrinsic value estimate still points to a sizeable discount. After the recent share price jump, does that gap reflect opportunity or justified caution from the market? ## Most Popular Narrative: 10.4% Overvalued Eisai closed at ¥4,949, which sits above the most followed fair value estimate of ¥4,482 built from long range earnings and margin assumptions. *Structural reforms and operational efficiencies, including a reduced R&D expense ratio and improved SG&A leverage, are increasing profitability and supporting management's ambition to achieve an 8% ROE target by FY2026. This suggests potential for margin expansion and greater earnings stability ahead.* *Positive long-term real-world and clinical data for LEQEMBI support not only greater physician and patient adoption but also strengthen Eisai's premium market positioning and pricing power, especially as healthcare spending continues to rise and stakeholders prioritize differentiated, high-impact therapies. This is described as driving both topline and profit expansion.* Read the complete narrative. Curious what sits behind that premium Alzheimer’s thesis? The narrative leans on specific revenue growth, fatter margins, and a future earnings multiple that needs careful scrutiny. **Result: Fair Value of ¥4,482 (OVERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, there are still clear pressure points, including global drug pricing scrutiny around LEQEMBI and Eisai's heavy reliance on a small group of key therapies. Find out about the key risks to this Eisai narrative. ## Another View on Eisai's Valuation The first narrative framed Eisai as 10.4% overvalued relative to a fair value of ¥4,482 based on long range earnings assumptions. Yet our DCF model presents a different perspective. At a share price of ¥4,949, Eisai appears at a 31.8% discount to an estimated future cash flow value of ¥7,261.22. Which story do you think better reflects the risk and reward you see in Eisai today? For a closer look at how this cash flow view is built and what would need to change for the gap to close, Look into how the SWS DCF model arrives at its fair value.. 4523 Discounted Cash Flow as at Aug 2026 Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Eisai for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 19 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. ## Next Steps With mixed signals across Eisai's fair value estimates and sentiment, this is a good time to review the data yourself and act promptly. To weigh up both sides of the story, use the full picture of Eisai's 2 key rewards and 1 important warning sign ## Looking for more investment ideas beyond Eisai? If Eisai has sharpened your focus on opportunities, do not stop here. The right mix of ideas can reshape your portfolio faster than you expect. - Target consistent income potential by scanning for companies in the 39 dividend fortresses that may support more reliable cash flows from distributions. - Spot potential value opportunities early by reviewing the 19 high quality undervalued stocks and see which businesses currently trade below their assessed worth. - Strengthen your downside protection by focusing on the 55 resilient stocks with low risk scores which highlights companies with lower overall risk profiles. *This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.* ### Valuation is complex, but we're here to simplify it. Discover if Eisai might be undervalued or overvalued with our detailed analysis, featuring **fair value estimates, potential risks, dividends, insider trades, and its financial condition.** Access Free Analysis ### Related Stocks - [4523.JP](https://longbridge.com/en/quote/4523.JP.md) ## Related News & Research - [Leqembi Iqlik® for initiation treatment launched in the US | B Stock News](https://longbridge.com/en/news/296790455.md) - [Eisai: Strong revenue and profit growth driven by key products and new market launches](https://longbridge.com/en/news/294650708.md) - [How Investors May Respond To Eisai (TSE:4523) Advancing Lecanemab Data And New CNS Oncology Filings](https://longbridge.com/en/news/292407767.md) - [What Eisai (TSE:4523)'s New Long‑Dated Bonds and UK Expansion Means For Shareholders](https://longbridge.com/en/news/289938779.md) - [Oncoinvent publishes corporate presentation on Radspherin alpha therapy for peritoneal metastases](https://longbridge.com/en/news/296475294.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**